Clinical Trials Browser

Phase 3 × Carcinoma, Hepatocellular × durvalumab × Clear all

NCT03847428 2026-03-06

EMERALD-2

Phase 3 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03778957 2026-01-16

EMERALD-1

Phase 3 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03298451 2026-01-14

HIMALAYA

Phase 3 Active not recruiting

1,324 enrolled 31 charts 1 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT05557838 2025-02-07

TREMENDOUS

Phase 3 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT05301842 2025-01-15

EMERALD-3

Phase 3 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms